cd38 inhibitor and 5-amino-1mq synergy nad+ The Pharmacology of CD38/NADase: An emerging target for cancer aging diseases SLC25A51 decouples the mitochondrial NAD+/NADH
SLC25A51 decouples the mitochondrial NAD+ NADH ratio to control proliferation of AML cells: Cell Metabolism Inhibition of CD38 by 78c Enhanced NAD+, Alleviated Inflammation, and Decreased Oxidative Stress in Old Murine Macrophages Induced by Oral Pathogens Small Molecule CD38 Inhibitors: Synthesis of 8 Amino N1 inosine 5 monophosphate, Analogues and Early Structure Activity Relationship CD38 Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+ Lowering Agents Evolving roles of CD38 metabolism in solid tumour microenvironment British Journal of Cancer
Pay in 4 interest-free payments of $7.39 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7




